Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Biotech Cannabis Stocks Rally More than 120%…Yesterday

Mar 15, 2016 • 11:46 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

After GW Pharmaceuticals (GWPH) reported overwhelmingly positive results from its first Phase 3 study on its Epidiolex product, several cannabis stocks rallied and we think this is just the start of something big.

Our rationale is based off of GWPH proving that cannabis should not be labeled as Schedule I substance. According to the DEA, Schedule I substances have high potential for abuse, no accepted medical treatment use, and a lack of accepted safety for use of the substance under medical supervision.

Reduces Seizures by 39%

GWPH said Epidiolex reduced the number of convulsive seizures in children with Dravet syndrome by 39%. Epidiolex is a pharmaceutical form of cannabidiol (CBD) which is one of the active ingredients in the cannabis plant.

Not only did these results prove that the cannabis plant has medical benefits but GWPH also developed an effective treatment for a debilitating illness that does not have an approved treatment. GWPH is also testing Epidiolex in Lennox-Gastaut Syndrome and Tuberous Sclerosis Complex, other rare forms of epilepsy.

Nasdaq Biotech Cannabis Stocks Rally

The results announced by GWPH had a significant impact on overall market sentiment and served as a catalyst to not only GWPH, but the entire cannabis industry.

Even though GWPH ended the day up more than 120%, they were not the biggest winner. Nasdaq traded Zynerba Pharmaceuticals (ZYNE) ended the day up approximately 150%. Insys Therapeutics (INSY) also benefited from this news and shares ended the day up 11%.

Time to Put CBD-Related Stocks on Your Radar

After analyzing the performance of more than 300 publicly traded cannabis stocks yesterday, we noticed that the biggest winners were levered to either the biotech or CBD industry. Some OTC stocks we want to highlight include:

Cannabis Sativa, Inc. (CBDS): Even though CBDS did not announce any news yesterday, shares rallied more than 240%. The company sells the Wild Earth Naturals line of CBD Water and are engaged in the research, development and licensing of specialized natural cannabis products.

CV Sciences, Inc. (CANV): Shares rallied more than 75% yesterday even though CANV did not announce any new developments. The company is focused on developing drugs that contain CBD and selling CBD-based consumer products.

Cannabis Science, Inc. (CBIS): After GWPH reported favorable results, CBIS applauded the company’s success and said it would speed up the regulatory process due to more research being made available for regulators. CBIS specializes in the development of cannabis-based medicines and the company said this will pave the way for them to move forward with their own testing in Europe and the United States. CBIS ended the day up more than 48% and we are monitoring trading closely.

Do Your Due Diligence

The cannabis industry is one of the most rapidly developing and controversial industries in the United States. Although there is a lot of opportunity in this sector, investors and traders need to their due diligence before creating a position.

On March 29-30, 2016, the MoneyShow is producing the Cannabis Investing Virtual Event in association with PR Newswire. The event features an impressive lineup of experts, analysts, and company executives. Click here to register for this free event and take advantage of a opportunity to learn about some of the top cannabis investments 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.